Glucagon-like peptide-1 receptor agonist drugs (commonly referred to as GLP-1 agonists) have become widely prescribed for ...

Bariatric surgery and GLP-1 drugs are associated with reductions in fat mass and a shift in body composition toward a higher ...

More than one-quarter of adults aged 25 to 64 years from 99 countries are eligible to receive a GLP-1 receptor agonist.

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for colorectal ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a lower risk for acute asthma exacerbations in ...

GLP-1 weight-loss drugs are in the news because so many people are using them to treat obesity and diabetes. With so many ...

In a retrospective study, patients with prior use of GLP-1 receptor agonists showed a significantly lower risk of developing ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of diabetic retinopathy. HealthDay News — For individuals with type 2 ...

Observational data indicate that GLP-1 receptor agonists might be beneficial for kidney transplant recipients with diabetes. GLP-1 receptor agonists are associated with better kidney graft and ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

An increased risk for nonarteritic anterior ischemic optic neuropathy was seen in association with 2 GLP-1 RAs (hazard ratios, 1.39 and 1.25 for semaglutide and liraglutide, respectively). HealthDay ...